Use of thromboelastography (TEG) for detection of new oral anticoagulants

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 5, 2015, Pages 665-673

  Dias, João D ^a   Norem, Katherine ^b   Doorneweerd, Derek D ^b   Thurer, Robert L ^b   Popovsky, Mark A ^b   Omert, Laurel A ^b,c,d  

^a Haemonetics SA   (Switzerland)

^b HAEMONETICS CORPORATION   (United States)

^c EINSTEIN MEDICAL CENTER   (United States)

^d CSL BEHRING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; APIXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; HUMAN; PROCEDURES; SENSITIVITY AND SPECIFICITY; THROMBOELASTOGRAPHY; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

ADOLESCENT; ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA INHIBITORS; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; SENSITIVITY AND SPECIFICITY; THIOPHENES; THROMBELASTOGRAPHY; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84928978230     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0170-OA     Document Type: Article

References (36)

1. th edition). Chest. 2008;133(6)(suppl):160S-198S.
2. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e44S-e88S. doi:10.1378/chest.11-2292.
3. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
4. Turpie AG, Eriksson BI, Lassen MR, Bauer KA. Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol. 2003;10(5):327-332.
5. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293(6):699-706.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
7. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, Suarez-Gea ML, Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis. 2013;2013:640723. doi:10.1155/2013/640723.
8. Ahmed S, Levin V, Malacoff R, Martinez MW. Dabigatran: a new chapter in anticoagulation. Cardiovasc Hematol Agents Med Chem. 2012;10(2):116-123.
9. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med. 2001;161(18):2215-2221.
10. Eriksson BI, Borris L, Dahl OE, et al. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4(1):121-128.
11. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820-829.
12. Bayer Pharma AG. XareltoW (rivaroxaban) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000944/WC500057108.pdf. Accessed June 12, 2014.
13. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69(17):1473-1484.
14. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365(21):2039-2040.
15. Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg. 2012;256(3):476-486.
16. Koster A, Buz S, Krabatsch T, et al. Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system. J Card Surg. 2008;23(4):321-323.
17. Choi TS, Khan AI, Greilich PE, Kroll MH. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery. Am J Clin Pathol. 2006;125(2):290-295.
18. Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) summary of product characteristics. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000829/WC500041059.pdf. Accessed June 12, 2014.
19. Boehringer Ingelheim Pharmaceuticals, Inc. Pradaxa (dabigatran etexilate) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022512s017lbl.pdf. Accessed June 12, 2014.
20. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295.
21. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10. doi:10.1186/1477-9560-11-10.
22. Janssen Pharmaceuticals, Inc. Xarelto (rivaroxaban) prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022406s004lbl.pdf. Accessed June 12, 2014.
23. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78(4):412-421.
24. Bristol-Myers Squibb/Pfizer EEIG. Eliquis (apixaban) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728.pdf. Accessed June 12, 2014.
25. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
26. Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med. 1997;130(4):401-411.
27. Chavez JJ, Foley DE, Snider CC, et al. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass. Anesth Analg. 2004;99(5):1290-1294.
28. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med. 2013;41(5):e42-e46. doi:10.1097/CCM.0b013e31827caaa3.
29. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127.
30. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit. 2010;32(6):673-679.
31. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34(7):489-498b. doi:10.1093/eurheartj/ehs408.
32. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108(1):191-198.
33. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107(2):379-387.
34. Neyens R, Bohm N, Cearley M, Andrews C, Chalela J. Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG) to guide decision-making. J Thromb Thrombolysis. 2014;37(2):80-83.
35. Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost. 2013;111(5):989-995.
36. Casutt M, Konrad C, Schuepfer G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist. 2012;61(11):948-953.